These data are consistent with our observations in R26mTmG/hAR:Osr1Cre/+ mice, and further support the regulatory role of aberrant AR activation in initiating prostatic tumorigenesis and promoting tumor growth and progression through elevating IGF1 and Wnt/β-catenin signaling pathways. The gene discussed is LYVE1; the disease is neoplasm.